Inflammation Inhibitors icon  

Eighth Annual

Inflammation Inhibitors

Small Molecule Approaches for Oral-Based Therapeutics

April 24-25, 2017


Interest in developing small molecule-based therapies for chronic inflammation remains strong despite the success of biologics for treating inflammation-related conditions such as rheumatoid arthritis. Small molecule agents, in contrast to biologics, can enter the cell and therefore act on intracellular targets which provides two advantages over biologics: 1) They can be developed into oral-based medications which are more convenient for the patient 2) There are a greater number of targets to aim at. Indeed a few oral-based kinase inhibitors for autoimmune indications were launched a few years ago and several more are in late stage development. This conference convenes medicinal chemists and discovery biologists to share their work and stay abreast of the rapid advances in developing new oral-based agents to combat different forms of chronic inflammation, which is at the nexus of several diseases.

Topics will include, but are not limited to:

  • Innate immunity targets (RORg, PPARs and other nuclear hormone receptors)
  • Intracellular kinase inhibitors (next-generation JAK inhibitors, BTK updates)
  • Inflammasome and other new targets (serine hydrolases, NOD2 receptors, MASP2)
  • Connections with the microbiome
  • Complement cascade and inflammation
  • Autoimmune disease oral-based drug candidates update (IBD/Chron’s, Lupus, RA, MS)
  • Neuroinflammation targets (LRRK2, NRL3P)
  • Fibrosis targets
  • Immuno-oncology/inflammation interplay

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 7, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

We hope you can join us for this day-and-a-half conference (one of four parallel tracks) that is in the first half of our larger Drug Discovery Chemistry event. Attending this meeting enables you to also hop to concurrent meeting tracks to hear other presentations of interest.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6252
Email: ashah@healthtech.com

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com